A prediction model could foresee adequate height response in children eligible for growth hormone treatment

Aim Prediction models may be useful in accurately identifying children who will benefit from growth hormone (GH) treatment. We aimed to validate the Gothenburg prediction model for this purpose. Methods The study included prepubertal children with GH deficiency who started treatment with GH during 2...

Full description

Saved in:
Bibliographic Details
Published in:Acta Paediatrica 2022-02, Vol.111 (2), p.346-353
Main Authors: Ly, Helena‐Jamin, Fors, Hans, Nilsson, Staffan, Dahlgren, Jovanna
Format: Article
Language:English
Subjects:
adolescence
age
birth
Body Height
Child
childhood
Children
deficiency
Dwarfism, Pituitary
Endocrinology and Diabetes
Endokrinologi och diabetes
Female
Growth Disorders
Growth Hormone
Growth hormones
Human Growth Hormone
Humans
Male
mathematical-model
Patients
Pediatrics
Pediatrik
prediction model
Prediction models
prepubertal children
reference values
secretion
short stature
validation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Prediction models may be useful in accurately identifying children who will benefit from growth hormone (GH) treatment. We aimed to validate the Gothenburg prediction model for this purpose. Methods The study included prepubertal children with GH deficiency who started treatment with GH during 2004‐2016 at Queen Silvia Children's Hospital, Gothenburg, based on a first‐year growth prediction of ≥0.7 SDS in height according to the Gothenburg prediction model on a GH dose of 33 μg/kg/day. Observed heights retrieved from medical charts were compared with predicted heights. Results The study included 121 patients (64% boys) with at least one year of data after the start of GH treatment. The median (range) GH dose was 30 (10–43) µg/kg/day for the first year and age at start of treatment was 5.32 (3–11.8) years. The model correctly excluded poor responders resulting in 119/121 (98%) patients having a height gain of at least ≥0.5 SDS in a year. However, the model underestimated relatively low predictions and overestimated relatively high predictions, with a residual standard deviation of 0.31 SDS. Conclusion By using a validated prediction model for GH in a clinical context, unnecessarily treating short children with an expected poor height outcome can be avoided.
ISSN:0803-5253
1651-2227
DOI:10.1111/apa.16070